{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:42:02Z","timestamp":1780389722913,"version":"3.54.1"},"reference-count":53,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"P2022-BMD\/7321 (Madrid\u2019s community)"},{"name":"ProACapital (Fundaci\u00f3n Starlite)"},{"name":"HALEKULANI, S. L."},{"name":"MJR"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Background and objectives: Duloxetine is widely used for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), and various types of neuropathic pain. While its efficacy is well documented in clinical trials, less is known about how it is perceived and utilized in routine psychiatric practice. To address this knowledge gap, we conducted a cross-sectional observational study involving 80 psychiatrists from Spain to assess real-world clinical attitudes toward duloxetine. Methods: Participants completed a 20-item multiple-choice questionnaire that examined familiarity, perceived efficacy in multiple conditions (MDD, GAD, neuropathic pain, somatization, and quality of life), and perspectives on tolerability, safety, adherence, and overall satisfaction. Results: Survey results indicated that a large majority of psychiatrists frequently prescribe duloxetine, particularly for patients with MDD and comorbid chronic pain. Notably, 94% rated it as either \u201cmore effective\u201d or \u201cmuch more effective\u201d for diabetic peripheral neuropathic pain. Psychiatrists reported a high perceived efficacy of duloxetine: 94% rated it as \u201cmore effective\u201d or \u201cmuch more effective\u201d for diabetic peripheral neuropathy, and 93% gave similarly positive ratings for general neuropathic pain. For somatization, 70% found it \u201ceffective\u201d or \u201cvery effective\u201d, and 83% observed improvements in quality of life for many of their patients. Psychiatrists generally reported favorable perceptions of duloxetine\u2019s tolerability profile: 97.5% rated it as the antidepressant associated with the least weight gain, and 82.5% perceived fewer sexual side effects compared to other options. Sedation and gastrointestinal side effects were generally considered mild or less severe. In terms of treatment adherence, 69% rated it as \u201cbetter\u201d or \u201cmuch better\u201d than other antidepressants, and 80% found its combination with other antidepressants to be \u201cfavorable\u201d or \u201cvery favorable\u201d. Overall satisfaction was high, with 99% of psychiatrists reporting being either \u201csatisfied\u201d or \u201cvery satisfied\u201d with its use. The side effect profile was generally viewed as manageable, with low perceived rates of weight gain, sedation, and sexual dysfunction. Furthermore, 96% of respondents expressed a willingness to recommend duloxetine to their colleagues. Conclusions: Psychiatrists reported highly favorable attitudes toward duloxetine, viewing it as a flexible treatment option in routine care. However, these findings reflect clinicians\u2019 subjective perceptions rather than objective clinical outcomes and should be interpreted accordingly.<\/jats:p>","DOI":"10.3390\/brainsci15070757","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:25:17Z","timestamp":1752751517000},"page":"757","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Delving into the Perception, Use, and Context of Duloxetine in Clinical Practice: An Analysis Based on the Experience of Healthcare Professionals"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-6397","authenticated-orcid":false,"given":"Oscar","family":"Fraile-Martinez","sequence":"first","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal\u00e1, 28801 Madrid, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-7855","authenticated-orcid":false,"given":"Cielo","family":"Garcia-Montero","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal\u00e1, 28801 Madrid, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Alvarez-Mon","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal\u00e1, 28801 Madrid, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"},{"name":"CIBERSAM-ISCIII (Biomedical Research Networking Centre in Mental Health), 28029 Madrid, Spain"},{"name":"Department of Psychiatry and Mental Health, University Hospital Infanta Leonor, 28031 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1708","authenticated-orcid":false,"given":"Miguel A.","family":"Ortega","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal\u00e1, 28801 Madrid, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1309-7510","authenticated-orcid":false,"given":"Melchor","family":"Alvarez-Mon","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcal\u00e1, 28801 Madrid, Spain"},{"name":"Ram\u00f3n y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain"},{"name":"Immune System Diseases-Rheumatology and Internal Medicine Service, University Hospital Prince of Asturias, 28805 Madrid, Spain"},{"name":"Networking Research Center on for Liver and Digestive Diseases (CIBEREHD), 28806 Alcala de Henares, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2491-8647","authenticated-orcid":false,"given":"Javier","family":"Quintero","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Mental Health, University Hospital Infanta Leonor, 28031 Madrid, Spain"},{"name":"Department of Legal and Psychiatry, Complutense University, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rodrigues-Amorim, D., Olivares, J.M., Spuch, C., and Rivera-Baltan\u00e1s, T. (2020). A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. Front. Psychiatry, 11.","DOI":"10.3389\/fpsyt.2020.554899"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/187152411798047807","article-title":"Duloxetine in the Treatment of Depression: An Overview","volume":"11","author":"Monteleone","year":"2011","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/14737175.2023.2211767","article-title":"Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions","volume":"23","author":"Fagan","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/AJP.0000000000000343","article-title":"Duloxetine in Painful Diabetic Neuropathy: A Systematic Review","volume":"32","author":"Hossain","year":"2016","journal-title":"Clin. J. Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s13018-023-03995-z","article-title":"Duloxetine for Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis","volume":"18","author":"Migliorini","year":"2023","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e7063","DOI":"10.5867\/medwave.2017.08.7063","article-title":"Is Duloxetine an Alternative in the Treatment of Osteoarthritis?","volume":"17","year":"2017","journal-title":"Medwave"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TCRM.S1458","article-title":"Factors Affecting Therapeutic Compliance: A Review from the Patient\u2019s Perspective","volume":"4","author":"Lin","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_8","first-page":"CD000011","article-title":"Interventions for Enhancing Medication Adherence","volume":"2014","author":"Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/00325481.2023.2189868","article-title":"Considerations When Selecting an Antidepressant: A Narrative Review for Primary Care Providers Treating Adults with Depression","volume":"135","author":"Montano","year":"2023","journal-title":"Postgrad. Med."},{"key":"ref_10","first-page":"CD014682","article-title":"Antidepressants for Pain Management in Adults with Chronic Pain: A Network Meta-analysis","volume":"2023","author":"Birkinshaw","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e26589","DOI":"10.2196\/26589","article-title":"Understanding Side Effects of Antidepressants: Large-Scale Longitudinal Study on Social Media Data","volume":"8","author":"Saha","year":"2021","journal-title":"JMIR Ment. Health"},{"key":"ref_12","first-page":"212245","article-title":"Efficacy and Safety of Duloxetine 60 Mg Once Daily in Major Depressive Disorder: A Review with Expert Commentary","volume":"2013","author":"Ball","year":"2013","journal-title":"Drugs Context"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and Pregabalin: High-Dose Monotherapy or Their Combination? The \u201cCOMBO-DN Study\u201d\u2014A Multinational, Randomized, Double-Blind, Parallel-Group Study in Patients with Diabetic Peripheral Neuropathic Pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4306\/pi.2016.13.4.447","article-title":"Effectiveness of Duloxetine Monotherapy Compared to Combination Therapy with Other Antidepressants in Patients with Major Depressive Disorder: A Short-Term, Retrospective Study","volume":"13","author":"Cheon","year":"2016","journal-title":"Psychiatry Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1185\/03007995.2011.645561","article-title":"Time Course of Improvement of Different Symptom Clusters in Patients with Major Depression and Pain Treated with Duloxetine or Placebo","volume":"28","author":"Demyttenaere","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4088\/JCP.v65n0411","article-title":"The Effect of Duloxetine on Painful Physical Symptoms in Depressed Patients: Do Improvements in These Symptoms Result in Higher Remission Rates?","volume":"65","author":"Fava","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2147\/NDT.S136448","article-title":"An Observational Study of Duloxetine Versus SSRI Monotherapy in Japanese Patients with Major Depressive Disorder: Subgroup Analyses of Treatment Effectiveness for Pain, Depressive Symptoms, and Quality of Life","volume":"13","author":"Kuga","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e240187","DOI":"10.57264\/cer-2024-0187","article-title":"A real-world analysis of antidepressant medications in US veterans aged 60 years and older: A comparative analysis","volume":"14","author":"Pittman","year":"2025","journal-title":"J. Comp. Eff. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"de Heer, E.W., Dekker, J., Beekman, A.T.F., van Marwijk, H.W.J., Holwerda, T.J., Bet, P.M., Roth, J., Timmerman, L., and van der Feltz-Cornelis, C.M. (2018). Comparative Effect of Collaborative Care, Pain Medication, and Duloxetine in the Treatment of Major Depressive Disorder and Comorbid (Sub)Chronic Pain: Results of an Exploratory Randomized, Placebo-Controlled, Multicenter Trial (CC:PAINDIP). Front. Psychiatry, 9.","DOI":"10.3389\/fpsyt.2018.00118"},{"key":"ref_20","first-page":"CD007115","article-title":"Duloxetine for Treating Painful Neuropathy, Chronic Pain or Fibromyalgia","volume":"2014","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Valenzuela-Fuenzalida, J.J., L\u00f3pez-Chaparro, M., Barahona-V\u00e1squez, M., Campos-Valdes, J., Cordero Gonzalez, J., Nova-Baeza, P., Orellana-Donoso, M., Suazo-Santiba\u00f1ez, A., Oyanedel-Amaro, G., and Guti\u00e9rrez Espinoza, H. (2024). Effectiveness of Duloxetine Versus Other Therapeutic Modalities in Patients with Diabetic Neuropathic Pain: A Systematic Review and Meta-Analysis. Pharmaceuticals, 17.","DOI":"10.3390\/ph17070856"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13643-023-02185-6","article-title":"Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Wu","year":"2023","journal-title":"Syst. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Li, X., Zhu, L., Zhou, C., Liu, J., Du, H., Wang, C., and Fang, S. (2018). Efficacy and Tolerability of Short-Term Duloxetine Treatment in Adults with Generalized Anxiety Disorder: A Meta-Analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194501"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/appy.12203","article-title":"Duloxetine in Treating Generalized Anxiety Disorder in Adults: A Meta-Analysis of Published Randomized, Double-Blind, Placebo-Controlled Trials","volume":"8","author":"Zhang","year":"2016","journal-title":"Asia-Pac. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpsychires.2019.08.009","article-title":"Comparative Efficacy and Acceptability of First-Line Drugs for the Acute Treatment of Generalized Anxiety Disorder in Adults: A Network Meta-Analysis","volume":"118","author":"He","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kong, W., Deng, H., Wan, J., Zhou, Y., Zhou, Y., Song, B., and Wang, X. (2020). Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.580858"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Muscatello, M.R.A., Zoccali, R.A., Pandolfo, G., Mangano, P., Lorusso, S., Cedro, C., Battaglia, F., Spina, E., and Bruno, A. (2019). Duloxetine in Psychiatric Disorders: Expansions beyond Major Depression and Generalized Anxiety Disorder. Front. Psychiatry, 10.","DOI":"10.3389\/fpsyt.2019.00772"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1586\/14737175.8.4.527","article-title":"Duloxetine in the Treatment of Major Psychiatric and Neuropathic Disorders","volume":"8","author":"Schennach","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jpsychires.2007.11.006","article-title":"Examining Quality of Life in Patients with Generalized Anxiety Disorder: Clinical Relevance and Response to Duloxetine Treatment","volume":"42","author":"Pollack","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of Duloxetine on Pain, Function, and Quality of Life among Patients with Chemotherapy-Induced Painful Peripheral Neuropathy: A Randomized Clinical Trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/nedt.2007.3.2.193","article-title":"Duloxetine in the Treatment of Major Depressive Disorder","volume":"3","author":"Goldstein","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/14740338.2011.582037","article-title":"Adverse Reactions to Duloxetine in Depression","volume":"10","author":"Bitter","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e082853","DOI":"10.1136\/bmjopen-2023-082853","article-title":"Beneficial and Harmful Effects of Duloxetine Versus Placebo, \u201cActive Placebo\u201d or No Intervention for Adults with Major Depressive Disorder: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomised Clinical Trials","volume":"15","author":"Siddiqui","year":"2025","journal-title":"BMJ Open"},{"key":"ref_34","first-page":"269","article-title":"Effects of the Antidepressant Duloxetine on Body Weight: Analyses of 10 Clinical Studies","volume":"8","author":"Wise","year":"2006","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Alvarez-Mon, M.A., Garc\u00eda-Montero, C., Fraile-Martinez, O., Quintero, J., Fernandez-Rojo, S., Mora, F., Guti\u00e9rrez-Rojas, L., Molina-Ruiz, R.M., Lahera, G., and \u00c1lvarez-Mon, M. (2023). Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists. Brain Sci., 13.","DOI":"10.3390\/brainsci13020333"},{"key":"ref_36","first-page":"e40933","article-title":"Serotonin Syndrome From Duloxetine Monotherapy: A Case Report","volume":"15","author":"Li","year":"2023","journal-title":"Cureus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WNF.0b013e31821b3aa0","article-title":"Serotonin Syndrome Due to Duloxetine","volume":"34","author":"Gelener","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"ref_38","first-page":"720","article-title":"Demystifying Serotonin Syndrome (or Serotonin Toxicity)","volume":"64","author":"Foong","year":"2018","journal-title":"Can. Fam. Physician"},{"key":"ref_39","first-page":"212","article-title":"The Safety and Tolerability of Duloxetine Compared with Paroxetine and Placebo: A Pooled Analysis of 4 Clinical Trials","volume":"8","author":"Nelson","year":"2006","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1743-6109.2007.00520.x","article-title":"ORIGINAL RESEARCH\u2014PSYCHOLOGY: Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder","volume":"4","author":"Clayton","year":"2007","journal-title":"J. Sex. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1368-5031.2006.00956.x","article-title":"Duloxetine 60 Mg Once Daily in the Treatment of Milder Major Depressive Disorder","volume":"60","author":"Perahia","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Oliva, V., Lippi, M., Paci, R., Del Fabro, L., Delvecchio, G., Brambilla, P., De Ronchi, D., Fanelli, G., and Serretti, A. (2021). Gastrointestinal Side Effects Associated with Antidepressant Treatments in Patients with Major Depressive Disorder: A Systematic Review and Meta-Analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 109.","DOI":"10.1016\/j.pnpbp.2021.110266"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/jcp.0b013e318160738e","article-title":"Safety and Tolerability of Duloxetine at 60 Mg Once Daily in Elderly Patients with Major Depressive Disorder","volume":"28","author":"Raskin","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1742-1241.2007.01476.x","article-title":"The Safety and Tolerability of Duloxetine in Depressed Elderly Patients with and without Medical Comorbidity","volume":"61","author":"Wise","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1185\/03007995.2011.576663","article-title":"Treatment Adherence and Persistence with Duloxetine, Venlafaxine XR, and Escitalopram among Patients with Major Depressive Disorder and Chronic Pain-Related Diseases","volume":"27","author":"Wang","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Szekeres, G., Rozsa, S., Dome, P., Barsony, G., and Gonda, X. (2021). A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients with Major Depressive Disorder or Generalized Anxiety Disorder. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.689143"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/CEOR.S52950","article-title":"Duloxetine Treatment Adherence across Mental Health and Chronic Pain Conditions","volume":"6","author":"Able","year":"2014","journal-title":"ClinicoEcon Outcomes Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/15622970701586331","article-title":"Non-Fatal Overdose of Duloxetine in Combination with Other Antidepressants and Benzodiazepines","volume":"10","author":"Menchetti","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_49","first-page":"PCC.11r01181","article-title":"Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: A meta-analysis of 11 double-blind, placebo-controlled clinical trials","volume":"13","author":"Ball","year":"2011","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e7313345331","DOI":"10.33448\/rsd-v13i3.45331","article-title":"Duloxetine: An Update","volume":"13","year":"2024","journal-title":"Res. Soc. Dev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2025.0033","article-title":"Circulating Blood-Based Proteins in Psychopathology and Cognition: A Mendelian Randomization Study","volume":"82","author":"Bhattacharyya","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_52","first-page":"e74541","article-title":"Efficacy of Supratherapeutic Duloxetine Combined with Cognitive-Behavioral Therapy in Severe Treatment-Resistant Obsessive-Compulsive Disorder with Comorbid Depression: A Case Report","volume":"16","author":"Bokhari","year":"2024","journal-title":"Cureus"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Cui, Y., Abdi, S.A.H., Wei, J., and Azhar, G. (2024). The Long-Term Cardiovascular Risks of Duloxetine Use in Older Adults: A Retrospective Medical Record-Based Adverse Drug Reaction Assessment. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247595"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/7\/757\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:11:04Z","timestamp":1760033464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/7\/757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["brainsci15070757"],"URL":"https:\/\/doi.org\/10.3390\/brainsci15070757","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}